These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24460691)

  • 1. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.
    Burford NT; Traynor JR; Alt A
    Br J Pharmacol; 2015 Jan; 172(2):277-86. PubMed ID: 24460691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allostery at opioid receptors: modulation with small molecule ligands.
    Livingston KE; Traynor JR
    Br J Pharmacol; 2018 Jul; 175(14):2846-2856. PubMed ID: 28419415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.
    Dietis N; Niwa H; Tose R; McDonald J; Ruggieri V; Filaferro M; Vitale G; Micheli L; Ghelardini C; Salvadori S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
    Br J Pharmacol; 2018 Jul; 175(14):2881-2896. PubMed ID: 29524334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies towards safer opioid analgesics-A review of old and upcoming targets.
    Varga BR; Streicher JM; Majumdar S
    Br J Pharmacol; 2023 Apr; 180(7):975-993. PubMed ID: 34826881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A promising chemical series of positive allosteric modulators of the μ-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects.
    Pryce KD; Kang HJ; Sakloth F; Liu Y; Khan S; Toth K; Kapoor A; Nicolais A; Che T; Qin L; Bertherat F; Kaniskan HÜ; Jin J; Cameron MD; Roth BL; Zachariou V; Filizola M
    Neuropharmacology; 2021 Sep; 195():108673. PubMed ID: 34153316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders.
    Pagare PP; Flammia R; Zhang Y
    Pharmacol Res; 2024 Jan; 199():107023. PubMed ID: 38081336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting multiple opioid receptors - improved analgesics with reduced side effects?
    Günther T; Dasgupta P; Mann A; Miess E; Kliewer A; Fritzwanker S; Steinborn R; Schulz S
    Br J Pharmacol; 2018 Jul; 175(14):2857-2868. PubMed ID: 28378462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
    Wang H; Cao D; Gillespie JC; Mendez RE; Selley DE; Liu-Chen LY; Zhang Y
    Future Med Chem; 2021 Mar; 13(6):551-573. PubMed ID: 33590767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Historical perspectives and recent advances in small molecule ligands of selective/biased/multi-targeted μ/δ/κ opioid receptor (2019-2022).
    He Y; Su Q; Zhao L; Zhang L; Yu L; Shi J
    Bioorg Chem; 2023 Dec; 141():106869. PubMed ID: 37797454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IUPHAR themed review: Opioid efficacy, bias, and selectivity.
    Ramos-Gonzalez N; Paul B; Majumdar S
    Pharmacol Res; 2023 Nov; 197():106961. PubMed ID: 37844653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative pain management via endocannabinoids in the time of the opioid epidemic: Peripheral neuromodulation and pharmacological interventions.
    Lee MT; Mackie K; Chiou LC
    Br J Pharmacol; 2023 Apr; 180(7):894-909. PubMed ID: 34877650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and dynamic insights into the activation of the μ-opioid receptor by an allosteric modulator.
    Kaneko S; Imai S; Uchikubo-Kamo T; Hisano T; Asao N; Shirouzu M; Shimada I
    Nat Commun; 2024 May; 15(1):3544. PubMed ID: 38740791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for developing μ opioid receptor agonists with reduced adverse effects.
    Yuan Y; Xu T; Huang Y; Shi J
    Bioorg Chem; 2024 Aug; 149():107507. PubMed ID: 38850778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches for probing allosteric interactions at 7 transmembrane spanning receptors.
    Klein MT; Vinson PN; Niswender CM
    Prog Mol Biol Transl Sci; 2013; 115():1-59. PubMed ID: 23415091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 1-(1-Arylimiazolin-2-Yl)-3-Arylalkilurea Derivatives with Modulatory Activity on Opioid MOP Receptors.
    Straszak D; Woźniak S; Siwek A; Głuch-Lutwin M; Kołaczkowski M; Pietrzak A; Drop B; Matosiuk D
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dualism, allosteric modulation, and biased signaling of opioid receptors: Future therapeutic potential.
    González AM; Jubete AG
    Rev Esp Anestesiol Reanim (Engl Ed); 2024 Apr; 71(4):298-303. PubMed ID: 37683976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid signaling and design of analgesics.
    Paul B; Sribhashyam S; Majumdar S
    Prog Mol Biol Transl Sci; 2023; 195():153-176. PubMed ID: 36707153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualizing ligand bias at the Mu-opioid receptor.
    Zamorano CA; Bruchas MR
    Cell; 2022 Nov; 185(23):4251-4253. PubMed ID: 36368303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel series of tunable µOR modulators with enhanced brain penetration for the treatment of opioid use disorder, pain and neuropsychiatric indications.
    Nerurkar A; Nguyen T; Wang S; Bhatt U; Li K; Li Y; Ding P; Seidl FJ; Holan M; Lee J; Widjaja T; Wei ZL; Sadlowski C; Sperandio D; McGee LR; Youngblood B; Schwartz N; Gehlert D; Medina JC
    Bioorg Med Chem Lett; 2023 Aug; 92():129405. PubMed ID: 37414346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing drugs and chemical probes with the dualsteric approach.
    Zha J; He J; Wu C; Zhang M; Liu X; Zhang J
    Chem Soc Rev; 2023 Dec; 52(24):8651-8677. PubMed ID: 37990599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.